SCHEMBL2948704

SCHEMBL2948704

CCC1OCC(c2cccc(C(=O)C(C(=O)c3cccc(F)c3)=C3Nc4ccccc4N3)c2)O1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.36
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35
PARP1 P09874 1/20 0.35
CYP1A2 P05177 1/20 0.31
GAA P10253 1/20 0.31
CYP2C9 P11712 1/20 0.31
HPGD P15428 1/20 0.31
CYP2C19 P33261 1/20 0.31
CTNNB1 P35222 2/20 0.31
WNT3A P56704 2/20 0.31
LMNA P02545 1/20 0.31
TSHR P16473 1/20 0.31
KDM1A O60341 1/20 0.31
RCOR1 Q9UKL0 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
KMT2A Q03164 3/20 0.30
MEN1 O00255 2/20 0.30
SCD5 Q86SK9 1/20 0.30
GRIN2B Q13224 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2946350 0.85 ALDH1A1 (0.37) CES2CES1PARP1CYP1A2GAA
SCHEMBL2945490 0.85 L3MBTL1 (0.36) L3MBTL1CES2CES1PARP1LMNA
SCHEMBL2944411 0.83 PARP1 (0.33) L3MBTL1CES2CES1PARP1CYP1A2
SCHEMBL2946343 0.80 L3MBTL1 (0.37) L3MBTL1CES2CES1PARP1KMT2A
SCHEMBL2949928 0.79 CES2 (0.38) L3MBTL1CES2CES1PARP1HPGD
SCHEMBL2941450 0.77 L3MBTL1 (0.35) L3MBTL1CES2CES1PARP1LMNA
SCHEMBL13239938 0.71 PARP1 (0.37) L3MBTL1PARP1
SCHEMBL2944822 0.70 CES2 (0.47) CES2CES1PARP1GAAHPGD
SCHEMBL4352918 0.69 CES2 (0.45) L3MBTL1CES2CES1PARP1CYP1A2
SCHEMBL2947404 0.68 CES2 (0.47) L3MBTL1CES2CES1PARP1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076367-B2 Benzimidazolylidene propane-1,3-dione derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2011-12-13 US disclosed
US-20100173946-A1 BENZIMIDAZOLYLIDENE PROPANE-1,3-DIONE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2010-07-08 US disclosed
US-7709519-B2 Benzimidazolylidene propane-1,3 dione derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2010-05-04 US disclosed
US-20090018177-A1 Propane-1,3-Dione Derivative or Salt Thereof ASTELLAS PHARMA INC. (JP) 2009-01-15 US disclosed
EP-1752452-A9 PROPANE-1,3-DIONE DERIVATIVE OR ITS SALT Astellas Pharma Inc. (JP) 2007-12-12 EP disclosed
EP-1752452-A1 PROPANE-1,3-DIONE DERIVATIVE OR ITS SALT Astellas Pharma Inc. (JP) 2007-02-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018177-A1 Propane-1,3-Dione Derivative or Salt Thereof GPER1, GNRHR, AR L3MBTL1 3232/4885CES2 4083/4885CES1 1983/4885
US-20100173946-A1 BENZIMIDAZOLYLIDENE PROPANE-1,3-DIONE DERIVATIVE OR SALT THEREOF GPER1, GNRHR, AR L3MBTL1 3155/4885CES2 4228/4885CES1 2243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.